<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/0B475401-BFC4-4998-A9A7-A1CA7B62D9E6"><gtr:id>0B475401-BFC4-4998-A9A7-A1CA7B62D9E6</gtr:id><gtr:name>Vantix Ltd.</gtr:name><gtr:address><gtr:line1>UNIT 4 ABBEY BARNS , DUXFORD ROAD</gtr:line1><gtr:city>ICKLETON</gtr:city><gtr:postCode>CB10 1SX</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0B475401-BFC4-4998-A9A7-A1CA7B62D9E6" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>0B475401-BFC4-4998-A9A7-A1CA7B62D9E6</gtr:id><gtr:name>Vantix Ltd.</gtr:name><gtr:address><gtr:line1>UNIT 4 ABBEY BARNS , DUXFORD ROAD</gtr:line1><gtr:city>ICKLETON</gtr:city><gtr:postCode>CB10 1SX</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>25000.0</gtr:offerGrant><gtr:projectCost>54667.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/A232E354-7155-42BE-94EA-947529415055"><gtr:id>A232E354-7155-42BE-94EA-947529415055</gtr:id><gtr:firstName>Grants</gtr:firstName><gtr:surname>Team</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=700024"><gtr:id>D264FC41-4230-4DE6-822A-55A686A8B66E</gtr:id><gtr:title>Vantix Real-time bacterial growth monitor</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>GRD Proof of Market</gtr:grantCategory><gtr:grantReference>700024</gtr:grantReference><gtr:abstractText>Market Research is needed to understand the strategic alignment of the novel technology that
Vantix is developing: an optical intensity fluctuation sensor for timely and accurate detection
and measurement of bacterial or fungal growth. We also need to know what the optimal
product profile is for any particular target market identified.
The system has great mass market potential in the medical, environmental and food quality
assurance sectors. It is ideally suited to measuring for example: urinary tract infections in real
time at a physicians clinic and also determine antibiotic susceptibility of any infection present.
The system currently has a limit of detection of ~1000cfu/ml E.coli in under 20minutes or
1cfu/ml in ~4hrs under optimal conditions.
Preliminary research shows that in the US nearly $500 million is spent on testing for urinary
tract infection and nearly the same again testing for antibiotic susceptibility, currently that
money does not go to the physician. We need to know if the ability to do this testing at the
physician?s office is something that would be accepted and if there are other similar or
alternative markets in different sectors.
The US has the biggest opportunities and is where we are focusing our other POC products. It
is essential to gather the best market information available using an organisation which knows
the commercial and competitive landscape well and have connections in the US as well as a
global outlook. Success in this endeavour will lead to significant export of the correct UK
developed product for the chosen market, and opens the rest of the world at the same time.
The system could find uses in a range of market sectors from: clinical to R&amp;amp;D, including
veterinary, pharmaceutical, environmental, industrial fermentation, food processing etc</gtr:abstractText><gtr:fund><gtr:end>2011-10-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2011-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>25000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">700024</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>